-
SCOPE Europe 2024 Best of Show Entries
Clinical Research News | The results are in: there are twelve new product finalists in the 2024 SCOPE Europe Best of Show awards that will be on display next week in Barcelona. Starting at the opening reception, the SCOPE Europe community is invited to identify exceptional innovation in technologies used by life science professionals, voting on the most impactful new products of the year.
Oct 24, 2024
-
Drug Developers Eying Rollout of AI Legislation in the EU
Clinical Research News | Eyes around the globe are on the EU Artificial Intelligence (AI) Act—the first comprehensive legal framework on AI anywhere—which will likely influence the direction of regulatory oversight measures adopted elsewhere, include other major markets such as the United States. Differing perspectives on the Act, including if and to what extent it could be a “death knell” for innovation, will be aired during a panel discussion being staged at the upcoming Summit for Clinical Ops Executives (SCOPE) Europe in Barcelona, Spain.
Oct 22, 2024
-
Estrogen’s Impact on Cancer Reveals New Treatment Options
Clinical Research News | A groundbreaking new approach for treating triple-negative breast cancer is moving forward, thanks to discoveries from Dr. Donald McDonnell’s lab at Duke University. Traditionally, hormone therapies have only been considered effective for estrogen receptor-positive cancers, but McDonnell’s research suggests that estrogen modulation could also impact TNBC.
Oct 17, 2024
-
Psst! Need a Simple and Reliable Eye Tracker for Your Brain Studies?
Clinical Research News | A mechanical engineer at the University of Houston is seeking physician collaborators with a research need for a small but sensitive wearable eye-tracking system to provide continuous data on human brain activity. The need was suggested by a survey of the literature, which found that a shortage of data coming from devices used in supervised clinical settings was resulting in inconclusive correlations study after study.
Oct 15, 2024
-
Catching Up With Jill Pellegrino, Now Leading AutoCruitment
Clinical Research News | For as long as most people can remember, patient enrollment into clinical trials has been abysmal—so much so that 80% of studies don’t finish on time and 55% end due to low accrual rates. The underlying issue is overreliance on study sites to find participants on their own.
Oct 10, 2024
-
CluePoints Launches Medical & Safety Review (MSR) Software
Clinical Research News | CluePoints has launched its Medical & Safety Review (MSR) tool that aims to simplify and streamline the medical analysis of study data through user-friendly dashboards, data manipulation and cleaning, query management and full transparency over the data history.
Oct 9, 2024
-
Curing Data Collection Woes Could Take a Village
Clinical Research News | The average clinical trial generates three times as much data as it did a decade ago, and yet there are no standards in place for how that information should be collected. That’s a big problem for many reasons, not the least of which is that drug developers may be missing key insights about the way interventions are working in individuals and across populations.
Oct 8, 2024
-
Study Aims to Resolve Variants of Uncertain Significance
Clinical Research News | A pioneering study led by Dr. Lachlan Jolly at the University of Adelaide’s Neurobiology Research Group is transforming genetic diagnostics by resolving variants of uncertain significance (VUS) using skin samples. Many patients with VUS lack a definitive diagnosis because RNA from disease-causing genes often can't be extracted from accessible tissues like blood or skin.
Oct 3, 2024
-
Scope of Things: Trial Planning Skews Conclusions, AI Diversity Help, News of the Month
Clinical Research News | In this month’s episode of the Scope of Things, host Deborah Borfitz covers everything you need to know about a pending launch of a large treatment trial for Graves’ disease, a recruitment campaign for a diagnostic tampon, Walgreens and BARDA’s new partnership, how eligibility criteria has been excluding people of African or Middle Eastern descent from cancer studies, and more.
Oct 2, 2024